Merck's Keytruda shown to extend lung cancer survival in two trials

CHICAGO (Reuters) - New trial results show that Merck& Co's Keytruda improves survival as a stand-alone treatment for newly diagnosed lung cancer and in combination with chemotherapy for hard-to-treat squamous cell lung cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news